Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044016 | 0.86 | FYN (0.49) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044158 | 0.86 | ROCK2 (0.47) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044078 | 0.85 | KLKB1 (0.46) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044491 | 0.84 | ATM (0.43) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044907 | 0.83 | ROCK2 (0.45) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044909 | 0.83 | ROCK2 (0.44) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044908 | 0.82 | ROCK2 (0.45) | METROCK2KLKB1ROCK1ATM | |
| SCHEMBL22044874 | 0.79 | ABL1 (0.43) | ABL1BCRLMNAL3MBTL1 | |
| SCHEMBL22044497 | 0.79 | MLYCD (0.48) | ROCK2ABL1BCRMAPK1 | |
| SCHEMBL22044160 | 0.79 | MET (0.42) | METROCK2KLKB1ROCK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | MET 299/4885ROCK2 1660/4885KLKB1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.